Trial Profile
A Phase 1, Dose-Finding Study of Folotyn (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Oct 2022
Price :
$35
*
At a glance
- Drugs Pralatrexate (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions
- Sponsors Acrotech Biopharma; Spectrum Pharmaceuticals
- 23 Jul 2021 Status changed from active, no longer recruiting to completed.
- 19 Mar 2020 Planned primary completion date changed from 1 Feb 2020 to 1 Aug 2020.
- 24 Sep 2019 Planned primary completion date changed from 1 Sep 2020 to 1 Feb 2020.